Vertex Pharmaceuticals SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KNov. 2, 2026, 4:05 p.m. ETView on SEC.gov Our explainer
Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedVertex Q3 2026 non-GAAP EPS of $4.76 and revenue of $3.44 billion in line with consensus; FY2026 revenue guidance raised to $13.15 to $13.25 billion, midpoint still below $13.28 billion consensus
8-KOct. 20, 2026, 4:09 p.m. ETView on SEC.gov
Departure/appointment of directors or officers
AI summary, unreviewedVertex Pharmaceuticals Adds Former Boston Scientific CFO Daniel Brennan to Board, Expanding Board to Eleven Members
8-KSept. 1, 2026, 4:25 p.m. ETView on SEC.gov
Departure/appointment of directors or officers
8-KAug. 3, 2026, 4:09 p.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits